CF PharmTech, Inc. disclosed a repurchase of 5,500 H-shares on 27 April 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange on the same date.

The shares were bought back on-market at prices ranging from HK$20.58 to HK$20.90, with a volume-weighted average cost of HK$20.73 per share. The aggregate consideration amounted to approximately HK$0.11 million.

Following the transaction, the company’s issued share capital (excluding treasury shares) decreased from 301.59 million to 301.59 million shares, while treasury shares increased from 631,500 to 637,000. The buy-back represents 0.0018% of the company’s outstanding shares prior to the transaction, leaving the total issued share count unchanged at 302.22 million.

The repurchase falls under the mandate approved by shareholders on 16 December 2025, which authorises the company to buy back up to 30.22 million shares. Including the latest transaction, CF PharmTech has repurchased 637,000 shares under this mandate, equivalent to 0.21% of the issued share base on the mandate date.

The company confirmed that the repurchase complied with Hong Kong Main Board Listing Rules and that a 30-day moratorium on new share issues or treasury share disposals will apply until 27 May 2026.